Skip to main content

Outlook Therapeutics Inc

For the period ended Aug 12, 2024. Filed Jun 26, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Aug 12, 2024 · Filed Jun 26, 2024

Use the contents to explore the available documents and sections.

OTLK$0.44-0.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

DEF 14A 1 tm2417053-2_def14a.htm DEF 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549​

​

SCHEDULE 14A

(RULE 14a-101)

SCHEDULE 14A INFORMATION

​

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐

Preliminary Proxy Statement

​

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

​

☒

Definitive Proxy Statement

​

☐

Definitive Additional Materials

​

☐

Soliciting Material Pursuant to §240.14a-12

​

OUTLOOK THERAPEUTICS, INC.

​

(Name of Registrant as Specified In Its Charter)

​

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

No fee required.

​

☐

Fee paid previously with preliminary materials.

​

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

​

111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830

(609) 619-3990

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

Dear Stockholder:

You are cordially invited to attend a special meeting of the stockholders, the Special Meeting, of Outlook Therapeutics, Inc., a Delaware corporation. The meeting will be held on Monday, August 12, 2024 at 9:00 a.m. Central Time at the offices of Cooley LLP, 110 N. Wacker Drive, Suite 4200, Chicago, Illinois 60606.

You are being asked to vote on the following matters:

(1)

To approve the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan; and

​

(2)

To conduct any other business properly brought before the Special Meeting and any adjournment or postponement thereof.

​

These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the Special Meeting is June 17, 2024. Only stockholders of record as of the close of business on that date may vote at the Special Meeting or any adjournment or postponement thereof.

By Order of the Board of Directors,

/s/ Lawrence A. Kenyon

​

Lawrence A. Kenyon

Corporate Secretary

Iselin, New Jersey

June 26, 2024

​​You are cordially invited to attend the Special Meeting in person. Whether or not you expect to attend the Special Meeting, please complete, date, sign and return the enclosed proxy, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the Special Meeting. Even if you have voted by proxy, you may still vote in person if you attend the Special Meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Special Meeting, you must obtain a proxy issued in your name from that record holder.​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.